Is cholesterol the major lipoprotein risk factor in coronary heart disease? - a Franco-Scottish overview

References

• Castelli W. P. Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. 1984; 76(2A)4–121. Castelli W. P. Epidemiology of coronary heart disease: the Framingham study. Am. J. Med. 1984; 76(2A)4–12
   PubMed Web of Science ®Google Scholar
• Assmann G., Schulte H., von Eckardstein A., Huang Y. High density lipo-protein cholesterol is a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11–S20, Suppl2. Assmann G., Schulte H., von Eckardstein A., Huang Y. High density lipo-protein cholesterol is a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11–S20, Suppl
   PubMed Web of Science ®Google Scholar
• Shepherd J., Cobbe S., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl J. Med. 1995; 333: 1301, 13073. Shepherd J., Cobbe S., Ford I., Isles C. G., Lorimer A. R., MacFarlane P. W., McKillop J. H., Packard C. J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl J. Med. 1995; 333: 1301, 1307
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383, 13894. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383, 1389
   PubMed Web of Science ®Google Scholar
• Sacks F. M., Pfeffer M. A., Moye L. A, Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M. O., Wun C.-C., Davis B. R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl J. Med. 1996; 335: 1001, 10095. Sacks F. M., Pfeffer M. A., Moye L. A, Rouleau J. L., Rutherford J. D., Cole T. G., Brown L., Warnica J. W., Arnold J. M. O., Wun C.-C., Davis B. R., Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl J. Med. 1996; 335: 1001, 1009
   PubMed Web of Science ®Google Scholar
• Hokanson J., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Curdiovas. Risk 1996; 3: 213, 2196. Hokanson J., Austin M. A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol: a meta-analysis of population-based prospective studies. J. Curdiovas. Risk 1996; 3: 213, 219
   PubMedGoogle Scholar
• Ericsson C. G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849, 8537. Ericsson C. G., Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347: 849, 853
   PubMed Web of Science ®Google Scholar
• Committee of Principal Investigators. A comparative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 1978; 40: 1069, 11188. Committee of Principal Investigators. A comparative trial in the primary prevention of ischaemic heart disease using clofibrate. Br. Heart J. 1978; 40: 1069, 1118
   PubMedGoogle Scholar
• Dorr A. E., Gundersen J., Schneider J. C., Spencer T. W., Martin W. B. Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J. Chron. Dis. 1978; 31: 5, 149. Dorr A. E., Gundersen J., Schneider J. C., Spencer T. W., Martin W. B. Colestipol hydrochloride in hypercholesterolemic patients. Effect on serum cholesterol and mortality. J. Chron. Dis. 1978; 31: 5, 14
   PubMedGoogle Scholar
• Lipid Research Clinics Program. The lipid research coronary primary prevention trial results. 1: Reduction in incidence of coronary heart disease. J. Amer. Med. Assoc. 1988; 251: 351, 36410. Lipid Research Clinics Program. The lipid research coronary primary prevention trial results. 1: Reduction in incidence of coronary heart disease. J. Amer. Med. Assoc. 1988; 251: 351, 364
   Google Scholar
• Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 1987; 317: 1237, 124511. Frick M. H., Elo O., Haapa K., Heinonen O. P., Heinsalmi P., Helo P., Huttunen J. K., Kaitaniemi P., Koskinen P., Manninen V. The Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 1987; 317: 1237, 1245
   PubMed Web of Science ®Google Scholar
• Manninen V., Tenkanen L., Koskinen P., Huttunen J. K., Manttari M., Heinonen O. P., Frick M. H. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37, 4512. Manninen V., Tenkanen L., Koskinen P., Huttunen J. K., Manttari M., Heinonen O. P., Frick M. H. Joint effects of serum triglyceride and LDL-cholesterol and HDL-cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Circulation 1992; 85: 37, 45
   PubMed Web of Science ®Google Scholar
• Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 1988; 223: 405, 41813. Carlson L. A., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 1988; 223: 405, 418
   PubMed Web of Science ®Google Scholar
• Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A, Smink R. D. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on surgical control of the hyperlipidernias (POSCH). N. Engl. J. Med. 1990; 323: 946, 95514. Buchwald H., Varco R. L., Matts J. P., Long J. M., Fitch L. L., Campbell G. S., Pearce M. B., Yellin A. E., Edmiston W. A, Smink R. D. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the program on surgical control of the hyperlipidernias (POSCH). N. Engl. J. Med. 1990; 323: 946, 955
   PubMed Web of Science ®Google Scholar
• Hahmann H. W., Bunte T., Hellwig N., Hau U., Becker D., Dyckmans J., Keller H. E., Schieffer H. J. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am. J. Cardiol. 1991; 67: 957, 96115. Hahmann H. W., Bunte T., Hellwig N., Hau U., Becker D., Dyckmans J., Keller H. E., Schieffer H. J. Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am. J. Cardiol. 1991; 67: 957, 961
   PubMed Web of Science ®Google Scholar
• MAAS investigators. Effect of simvastatin on coronary atheroma; the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633, 63816. MAAS investigators. Effect of simvastatin on coronary atheroma; the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633, 638
   PubMed Web of Science ®Google Scholar
• Pitt B., Mancini J., Ellis S. G., Rosman H. S., Park J. S., McGovem M. E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 1995; 26: 1133, 113917. Pitt B., Mancini J., Ellis S. G., Rosman H. S., Park J. S., McGovem M. E. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 1995; 26: 1133, 1139
   PubMed Web of Science ®Google Scholar
• Jukema J. W., Bruschke A. V., van Boven A. J., Reiber J. H., Bal E. T., Zwinderman A. H., Jansen H., Boerma G. J., van Rappard F. M., Lie K. I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. REGRES. Circulation 1995; 91: 2528, 254018. Jukema J. W., Bruschke A. V., van Boven A. J., Reiber J. H., Bal E. T., Zwinderman A. H., Jansen H., Boerma G. J., van Rappard F. M., Lie K. I. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. REGRES. Circulation 1995; 91: 2528, 2540
   PubMed Web of Science ®Google Scholar
• Farnier M., Bonnefous F., Debbas N., Irvine A. Comparative efficacy and safety of micronised fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidaemia. Arch. Int. Med. 1994; 154: 441, 44919. Farnier M., Bonnefous F., Debbas N., Irvine A. Comparative efficacy and safety of micronised fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidaemia. Arch. Int. Med. 1994; 154: 441, 449
   PubMed Web of Science ®Google Scholar
• Lee A. J., Lowe G. D. O., Woodward M. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br. Heart J. 1993; 69: 338, 34220. Lee A. J., Lowe G. D. O., Woodward M. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br. Heart J. 1993; 69: 338, 342
   PubMedGoogle Scholar
• Tallis G. A. Atherogenicity of triglyceride-rich lipoproteins. J. Cardiovasc. Risk 1994; 1: 202, 20621. Tallis G. A. Atherogenicity of triglyceride-rich lipoproteins. J. Cardiovasc. Risk 1994; 1: 202, 206
   PubMedGoogle Scholar
• Ihnken K., Speiser W., Ruf W. High PA1 activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of acute myocardial infarction. Ann. Hematol. 1993; 67: 237, 24422. Ihnken K., Speiser W., Ruf W. High PA1 activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of acute myocardial infarction. Ann. Hematol. 1993; 67: 237, 244
   PubMed Web of Science ®Google Scholar
• Fuster V., Badimon L., Badimon J. J., Chesboro J. H. The pathogenesis of coronary artery disease and the acute coronary syndrome. New Engl J. Med. 1992; 326: 242, 24423. Fuster V., Badimon L., Badimon J. J., Chesboro J. H. The pathogenesis of coronary artery disease and the acute coronary syndrome. New Engl J. Med. 1992; 326: 242, 244
   PubMed Web of Science ®Google Scholar